1M6MYTD1Y5YMAX
Loading quotes...
Forecast
The analysts' average price target is €11.51 (+66.81%). The median is €3.45 (-50.00%).
| Buy |
0 |
| Hold |
5 |
| Sell |
0 |
News Go to news feed
There is currently no news available for this company. We are working on adding more providers to change this.
Financials
| (EUR) | Jun 2026 | |
|---|---|---|
| Revenue | 0 | - |
| Gross profit | 0 | 100.00% |
| Net profit | -16.65M | 181.79% |
| EBITDA | -17.04M | 196.93% |
Fundamentals
| Metric | Value |
|---|---|
Market capitalization | €22.98M |
Number of shares | 3.94M |
52-week high/low | €7.22 - €1.89 |
| Dividends | No |
Beta | 2.80 |
P/E ratio | -0.24 |
PEG ratio | 0.00 |
P/B ratio | 0.99 |
P/S ratio | 0.00 |
Company profile
| Name | ATHIRA PHARMA INC. -,0001 |
| CEO | Mark J. Litton |
| Employees | 26 |
Discover assets
Shareholders of ATHIRA PHARMA INC. -,0001 also invest in the following assets
